[{"address1": "245 Main Street", "address2": "Second Floor", "city": "Cambridge", "state": "MA", "zip": "02142", "country": "United States", "phone": "617 500 8080", "website": "https://immuneering.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.", "fullTimeEmployees": 66, "companyOfficers": [{"maxAge": 1, "name": "Dr. Benjamin J. Zeskind M.B.A., Ph.D.", "age": 42, "title": "Co-Founder, President, CEO & Director", "yearBorn": 1982, "fiscalYear": 2023, "totalPay": 935085, "exercisedValue": 0, "unexercisedValue": 1146738}, {"maxAge": 1, "name": "Mr. Robert J. Carpenter M.B.A., M.S.", "age": 78, "title": "Co-Founder & Chair Emeritus", "yearBorn": 1946, "fiscalYear": 2023, "totalPay": 75357, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Brett M. Hall Ph.D.", "age": 56, "title": "Chief Scientific Officer", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 905415, "exercisedValue": 0, "unexercisedValue": 1402731}, {"maxAge": 1, "name": "Mr. Harold E. Brakewood", "age": 58, "title": "Chief Business Officer", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 579769, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Mallory  Morales CPA", "age": 40, "title": "Principal Financial & Accounting Officer, Chief Accounting Officer and Treasurer", "yearBorn": 1984, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Paula  George CPA", "title": "Director of Accounting & Operations and Assistant Corporate Controller", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael D. Bookman J.D.", "age": 37, "title": "Chief Legal Officer & Secretary", "yearBorn": 1987, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Leah R. Neufeld", "age": 51, "title": "Chief People Officer", "yearBorn": 1973, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peter  King Ph.D.", "title": "Head of Discovery & VP", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Praveen  Nair Ph.D.", "title": "Head of Translational Pharmacology & VP", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 6, "compensationRisk": 10, "shareHolderRightsRisk": 7, "overallRisk": 8, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.86, "open": 1.9, "dayLow": 1.85, "dayHigh": 1.92, "regularMarketPreviousClose": 1.86, "regularMarketOpen": 1.9, "regularMarketDayLow": 1.85, "regularMarketDayHigh": 1.92, "beta": -0.366, "forwardPE": -1.2015504, "volume": 167977, "regularMarketVolume": 167977, "averageVolume": 2053384, "averageVolume10days": 340930, "averageDailyVolume10Day": 340930, "bid": 1.82, "ask": 1.92, "bidSize": 100, "askSize": 100, "marketCap": 57753744, "fiftyTwoWeekLow": 1.0, "fiftyTwoWeekHigh": 7.68, "fiftyDayAverage": 2.0275, "twoHundredDayAverage": 1.739575, "currency": "USD", "enterpriseValue": 11337127, "floatShares": 22397620, "sharesOutstanding": 31050400, "sharesShort": 2160941, "sharesShortPriorMonth": 1755894, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.0696, "heldPercentInsiders": 0.27813998, "heldPercentInstitutions": 0.13994999, "shortRatio": 0.46, "shortPercentOfFloat": 0.0921, "impliedSharesOutstanding": 32521300, "bookValue": 1.859, "priceToBook": 1.000538, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -58068616, "trailingEps": -1.97, "forwardEps": -1.64, "enterpriseToEbitda": -0.185, "52WeekChange": -0.7248521, "SandP52WeekChange": 0.22903383, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "IMRX", "underlyingSymbol": "IMRX", "shortName": "Immuneering Corporation", "longName": "Immuneering Corporation", "firstTradeDateEpochUtc": 1627651800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "e5829551-96d1-35fc-9c6d-d258079bf8f6", "messageBoardId": "finmb_308350677", "gmtOffSetMilliseconds": -18000000, "currentPrice": 1.86, "targetHighPrice": 25.0, "targetLowPrice": 1.5, "targetMeanPrice": 11.91667, "targetMedianPrice": 12.0, "recommendationMean": 2.14286, "recommendationKey": "buy", "numberOfAnalystOpinions": 6, "totalCash": 50657732, "totalCashPerShare": 1.631, "ebitda": -61426520, "totalDebt": 4241026, "quickRatio": 7.321, "currentRatio": 7.986, "debtToEquity": 7.347, "returnOnAssets": -0.42354, "returnOnEquity": -0.71806, "freeCashflow": -32061940, "operatingCashflow": -52264260, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-15"}]